This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Pancreatic Adenocarcinoma Non-resectable
and you are
under 90
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This is a single arm phase II trial assessing the potential activity of combination PEGPH20 plus Gemcitabine with radiotherapy in ten patients with localized, unresectable pancreatic adenocarcinoma.

Provided treatments

  • Drug: PEGylated Recombinant Human Hyaluronidase (PEGPH20)
  • Drug: Gemcitabine
  • Radiation: Radiation

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02910882. The sponsor of the trial is Scripps Health and it is looking for 4 volunteers for the current phase.
Official trial title:
A Phase II Study Combining PEGPH20 With Concurrent Gemcitabine and Radiotherapy in Patients With Localized, Unresectable Pancreatic Adenocarcinoma